- Home
- AMAL vs NRIX Comparison
AMAL vs NRIX Comparison
Compare AMAL & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMAL
- NRIX
- Stock Information
- Founded
- AMAL 1923
- NRIX 2009
- Country
- AMAL United States
- NRIX United States
- Employees
- AMAL N/A
- NRIX N/A
- Industry
- AMAL Commercial Banks
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- AMAL Finance
- NRIX Health Care
- Exchange
- AMAL Nasdaq
- NRIX Nasdaq
- Market Cap
- AMAL 858.7M
- NRIX 728.6M
- IPO Year
- AMAL 2018
- NRIX 2020
- Fundamental
- Price
- AMAL $27.58
- NRIX $8.44
- Analyst Decision
- AMAL Hold
- NRIX Strong Buy
- Analyst Count
- AMAL 2
- NRIX 14
- Target Price
- AMAL $33.00
- NRIX $29.07
- AVG Volume (30 Days)
- AMAL 149.9K
- NRIX 761.7K
- Earning Date
- AMAL 10-23-2025
- NRIX 10-10-2025
- Dividend Yield
- AMAL 1.99%
- NRIX N/A
- EPS Growth
- AMAL 3.73
- NRIX N/A
- EPS
- AMAL 3.34
- NRIX N/A
- Revenue
- AMAL $304,724,000.00
- NRIX $88,381,000.00
- Revenue This Year
- AMAL $9.82
- NRIX $74.59
- Revenue Next Year
- AMAL $11.11
- NRIX N/A
- P/E Ratio
- AMAL $8.44
- NRIX N/A
- Revenue Growth
- AMAL 4.35
- NRIX 41.86
- 52 Week Low
- AMAL $25.03
- NRIX $8.18
- 52 Week High
- AMAL $38.19
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- AMAL 36.51
- NRIX 34.28
- Support Level
- AMAL $28.32
- NRIX $8.90
- Resistance Level
- AMAL $29.19
- NRIX $10.13
- Average True Range (ATR)
- AMAL 0.60
- NRIX 0.47
- MACD
- AMAL -0.06
- NRIX -0.03
- Stochastic Oscillator
- AMAL 6.07
- NRIX 6.11
About AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management and trust and custody services.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.